Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant

NCT02181413 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02181413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02181413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
July 16, 2014
Completion date
September 8, 2023
Enrollment
656 (actual)
Sites
227

Conditions

As the registry lists them; a condition with its own page is linked.

autologous stem cell transplant, multiple myeloma